{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:14:10Z","timestamp":1782562450618,"version":"3.54.5"},"reference-count":21,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,8,3]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Ovarian cancer is the second the most common gynaecological malignancy in developed countries. 70% of patients relapse in the first 3 years following debulking surgery and first-line chemotherapy. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer susceptibility gene (<jats:italic>BRCA<\/jats:italic>), and is now recommended as maintenance treatment in patients with platinum-sensitive relapse of ovarian cancer. It has been shown to increase progression-free survival. We present a case of a 68-year-old woman with brain metastases from high-grade serous ovarian cancer who has remained free of disease progression for longer than 17 months with niraparib use as maintenance treatment after second-line chemotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2019-230738","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T07:36:57Z","timestamp":1567064217000},"page":"e230738","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases"],"prefix":"10.1136","volume":"12","author":[{"given":"Simon","family":"Gray","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Ying","family":"Khor","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Yiannakis","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"2025082801185055000_12.8.e230738.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"2025082801185055000_12.8.e230738.2","unstructured":"Cancer Resarch UK. Ovarian Cancer Statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer (Accessed 03 Feb 2019)."},{"key":"2025082801185055000_12.8.e230738.3","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.22371","article-title":"Development of an ovarian cancer symptom index: possibilities for earlier detection","volume":"109","author":"Goff","year":"2007","journal-title":"Cancer"},{"key":"2025082801185055000_12.8.e230738.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"2025082801185055000_12.8.e230738.5","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1995.1134"},{"key":"2025082801185055000_12.8.e230738.6","unstructured":"National Institute for Health and Care Excellence. Ovarian Cancer Overview. https:\/\/pathways.nice.org.uk\/pathways\/ovarian-cancer (Accessed Feb 2019)."},{"key":"2025082801185055000_12.8.e230738.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010119","article-title":"Platinum Resistance in Ovarian Cancer: Role of DNA Repair","volume":"11","author":"Damia","year":"2019","journal-title":"Cancers"},{"key":"2025082801185055000_12.8.e230738.8","unstructured":"National Institute for Health and Care Excellence. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [TA528]. https:\/\/www.nice.org.uk\/guidance\/ta528 (Accessed Feb 2019)."},{"key":"2025082801185055000_12.8.e230738.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"2025082801185055000_12.8.e230738.10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: testing, implications and treatment considerations","volume":"9","author":"Neff","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 1","key":"2025082801185055000_12.8.e230738.11","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2018\/e450s","article-title":"Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management","volume":"73","author":"da Cunha Colombo Bonadio","year":"2018","journal-title":"Clinics"},{"key":"2025082801185055000_12.8.e230738.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"2025082801185055000_12.8.e230738.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"2025082801185055000_12.8.e230738.14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025082801185055000_12.8.e230738.15","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"2025082801185055000_12.8.e230738.16","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"2025082801185055000_12.8.e230738.17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025082801185055000_12.8.e230738.18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gore.2016.10.004","article-title":"Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease","volume":"18","author":"Bangham","year":"2016","journal-title":"Gynecol Oncol Rep"},{"key":"2025082801185055000_12.8.e230738.19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jog.13851","article-title":"Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report","volume":"45","author":"Sakamoto","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"2025082801185055000_12.8.e230738.20","unstructured":"UpToDate. Medical treatment for relapse epithelial ovarian, fallopian tubal or peritoneal cancer. https:\/\/www.uptodate.com\/contents\/medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-sensitive-disease#H421525877 (Accessed Mar 2019)."},{"key":"2025082801185055000_12.8.e230738.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30559-9"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-230738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:19:02Z","timestamp":1756369142000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-230738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,28]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bcr-2019-230738"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-230738","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}